Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.

Valeria MerzFrancesca MainesStefano MarcucciChiara SartoriMichela FrisinghelliChiara TrentinDzenete KadrijaFrancesco Giuseppe CarboneAndrea MichielanArmando GabbrielliDavide MelisiMattia BarbareschiAlberto BroleseOrazio Caffo

Published in: Journal of cancer research and clinical oncology (2024)

Treatment of PACC should be tailored based on the peculiar molecular features that distinguish PACC from ductal adenocarcinoma. Evaluation of potentially therapeutically targetable alterations should be mandatory in case of PACC diagnosis.

Keyphrases

single molecule
combination therapy
radiation therapy
replacement therapy
epidermal growth factor receptor